Marina Kremyanskaya is an Oncology physician affiliated with Mount Sinai Hospital. OpenAlex indexes 284 publications with 2,386 citations (h-index 27); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 E 102nd St
New York, NY 100296030
Telephone
212-241-6756Registry record last updated 22 Feb 2019.
Clinical trials
- Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Sponsor: Icahn School of Medicine at Mount Sinai
- Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Sponsor: Marina Kremyanskaya
- Ruxolitinib in Combination With Autotransplant
Sponsor: Marina Kremyanskaya
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20256 payments
- Incyte CorporationProgram year20253 payments
- Daiichi Sankyo Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
27.8%Azole Antifungal15.1%Posaconazole100%Part D<11 patientsFluoroquinolone Antibacterial9.2%Levofloxacin100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
25.9%Antimetabolite16.7%Hydroxyurea100%Part D≥18 patientsKinase inhibitor9.2%Sprycel50%Jakafi50%Part D<11 patientsDermatology
9.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor9.7%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Allison McGeer
Mount Sinai Hospital
Scott Sicherer, MD
Mount Sinai Hospital
Ulrich Specks
Mount Sinai Hospital
Jorge Sánchez‐Guerrero
Mount Sinai Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”